The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma.
Shota Tanaka
No relevant relationships to disclose
Tracy Batchelor
Consultant or Advisory Role - Advanced Medical; Champions Biotechnology; Kyowa Hakko Kirin; Merck; Roche; Spectrum Pharmaceuticals
Honoraria - American Society of Hematology; Educational Concepts Group; Oakstone Medical Publishing; Research to Practice; Robert Michael Educational Institute LLC; UpToDate
Research Funding - AstraZeneca; Millennium; Pfizer
Anthony John Iafrate
Consultant or Advisory Role - Bio-Reference Laboratories
Dora Dias-Santagata
Consultant or Advisory Role - Bio-Reference Laboratories
Darrell R. Borger
Consultant or Advisory Role - Bio-Reference Laboratories
Leif William Ellisen
Honoraria - Bio-Reference Laboratories; GenPath
Daniel Yang
No relevant relationships to disclose
David N. Louis
No relevant relationships to disclose
Daniel P. Cahill
No relevant relationships to disclose
Andrew S. Chi
Research Funding - Pfizer
Expert Testimony - Pfizer